Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
March 02, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
January 11, 2022 08:00 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a...
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
December 13, 2021 16:05 ET
|
Harpoon Therapeutics
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at...
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
December 11, 2021 09:00 ET
|
Harpoon Therapeutics
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable...
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
November 04, 2021 09:00 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
June 04, 2021 16:00 ET
|
Harpoon Therapeutics
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:04 ET
|
Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors
March 24, 2021 17:09 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
March 11, 2021 13:16 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021 16:05 ET
|
Harpoon Therapeutics
Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first...